GSK 650394 Inhibits Osteoclasts Differentiation and Prevents Bone Loss via Promoting the Activities of Antioxidant Enzymes In Vitro and In Vivo

Figure 5

GSK inhibited the activation of NF-κB, MAPK, and NFATc1 signaling pathways during the procedure of osteoclastic differentiation. (a) Average intensity ratio of phosphorated-Ikkβ to Ikkβ, phosphorated-p65 to p65, and IkBα to GAPDH in BMMs pretreated with/without 5 μM GSK and stimulated by RANKL after 10, 20, 40, and 60 mins. (b–d) Quantitative of protein intensity. (e) Average intensity ratio of phosphorated-ERK to total ERK, phosphorated-JNK to total JNK, and phosphorated-p38 to total p38 in BMMs at the presence of 5 μM GSK or not and stimulated by RANKL after 10, 20, 40, and 60 mins. (f–h) Protein intensity was analyzed using Image J software. (i) Expression level of NFATc1 in BMMs at the presence of 5 μM GSK for 1, 3, or 5 days. (j) Protein intensity for NFATc1 was quantified using Image J software. , vs control.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)